litlas
Log inCreate account

Christian Kollmannsberger

Active 1998–2025

147
Papers
34,353
Citations
82
h-index
142
i10-index

Citations

Citations per year for Christian Kollmannsberger1998: 1 citations1999: 7 citations2000: 9 citations2001: 17 citations2002: 12 citations2003: 34 citations2004: 22 citations2005: 33 citations2006: 43 citations2007: 45 citations2008: 53 citations2009: 43 citations2010: 69 citations2011: 60 citations2012: 88 citations2013: 79 citations2014: 118 citations2015: 147 citations2016: 275 citations2017: 322 citations2018: 416 citations2019: 1,433 citations2020: 1,793 citations2021: 1,613 citations2022: 1,257 citations2023: 866 citations2024: 1,348 citations2025: 579 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,972 citing papers, 23.2% of this breakdownChina: 1,236 citing papers, 9.7% of this breakdownItaly: 776 citing papers, 6.1% of this breakdownUnited Kingdom: 741 citing papers, 5.8% of this breakdownFrance: 687 citing papers, 5.4% of this breakdownGermany: 652 citing papers, 5.1% of this breakdownJapan: 597 citing papers, 4.7% of this breakdownCanada: 582 citing papers, 4.5% of this breakdownSpain: 463 citing papers, 3.6% of this breakdownNetherlands: 364 citing papers, 2.8% of this breakdownAustralia: 360 citing papers, 2.8% of this breakdownSwitzerland: 244 citing papers, 1.9% of this breakdown
0%23.2%Other 24.4%

Institutions

Fields

  • Medicine80.5%
  • Biochemistry, Genetics and Molecular Biology11.7%
  • Immunology and Microbiology4.2%
  • Neuroscience1%
  • Engineering0.4%
  • Materials Science0.3%
  • Other1.9%

Topics

  • Cancer Immunotherapy and Biomarkers15%
  • Renal cell carcinoma treatment8.7%
  • Immunotherapy and Immune Responses3.7%
  • CAR-T cell therapy research3.3%
  • Ferroptosis and cancer prognosis3.3%
  • Cancer Genomics and Diagnostics3.2%
  • Other62.8%

Coauthors

All papers

Open in search
  1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 cited by 4,643

  2. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma - New England Journal of Medicine 2015 cited by 5,890

  3. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri - New England Journal of Medicine 2019 cited by 2,550

  4. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Authors: Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir - Cancer 2022 cited by 263

  5. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Authors: Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark Warren, Ali Golshayan, Chakshu Sahi, Bernhard J. Eigl, Joseph D. Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N., Christian Kollmannsberger, David F. McDermott, William Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri - Journal of Clinical Oncology 2009 cited by 2,130

  6. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

    Authors: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, Shruti Shally Saggi, M. Brent McHenry, Robert J. Motzer - ESMO Open 2020 cited by 522

  7. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Authors: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 cited by 780

  8. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

    Authors: Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Evan W. Warner, Katherine Sunderland, Christian Kollmannsberger, Bernhard J. Eigl, Daygen L. Finch, Conrad D. Oja, Joanna Vergidis, Muhammad Zulfiqar, Arun Azad, Matti Nykter, Martin Gleave, Alexander W. Wyatt, Kim N. - Cancer Discovery 2018 cited by 522

  9. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

    Authors: Toni K. Choueiri, Robert J. Motzer, Brian I. Rini, John B.A.G. Haanen, Matthew T. Campbell, B. Venugopal, Christian Kollmannsberger, Gwénaëlle Gravis, Mamoru Uemura, J.L. Lee, Marc‐Oliver Grimm, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Sumanta K. Pal, J. Wang, Mariangela Mariani, S. Krishnaswami, Paul Cislo, A. Chudnovsky, Camilla Fowst, Bo Huang, Alessandra di Pietro, Laurence Albigès - Annals of Oncology 2020 cited by 461

  10. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    Authors: Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Cancer 2020 cited by 337

  11. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Authors: Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Lauren C. Harshman, Georg A. Bjarnason, Ulka N. Vaishampayan, Mary J. MacKenzie, Lori Wood, Frede Donskov, Min-Han Tan, Sun Young Rha, Neeraj Agarwal, Christian Kollmannsberger, Brian I. Rini, Toni K. Choueiri - The Lancet Oncology 2013 cited by 1,029

  12. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

    Authors: Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts, Wilson Tu, William R. S. Fan, Andrew J. Murtha, Catarina Kollmannsberger, Edmond M. Kwan, Karan Parekh, Elena Schönlau, Cecily Q. Bernales, Gráinne Donnellan, Sarah W.S. Ng, Takayuki Sumiyoshi, Joanna Vergidis, Krista Noonan, Daygen L. Finch, Muhammad Zulfiqar, Stacy Miller, Sunil Parimi, Jean‐Michel Lavoie, Edward Hardy, Maryam Soleimani, Lucia Nappi, Bernhard J. Eigl, Christian Kollmannsberger, Sinja Taavitsainen, Matti Nykter, Sofie H. Tolmeijer, Emmy Boerrigter, Niven Mehra, Nielka P. van Erp, Bram De Laere, Johan Lindberg, Henrik Grönberg, Daniel Khalaf, Matti Annala, Kim N., Alexander W. Wyatt - Nature Communications 2024 cited by 120

  13. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

    Authors: Daniel Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L. Finch, Conrad D. Oja, Joanna Vergidis, Muhammad Zulfiqar, Katherine Sunderland, Arun Azad, Christian Kollmannsberger, Bernhard J. Eigl, Krista Noonan, Deepa Wadhwa, Andrew Attwell, Bruce Keith, Susan Ellard, Lyly Le, Martin Gleave, Alexander W. Wyatt, Kim N. - The Lancet Oncology 2019 cited by 352

  14. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

    Authors: Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, for the CLEAR Trial Investigators, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler and 141 more - Journal of Clinical Oncology 2024 cited by 158

  15. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

    Authors: Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin H. Voss, Padmanee Sharma, Sumanta K. Pal, Albiruni R. Abdul Razak, Christian Kollmannsberger, Daniel Y.C. Heng, Jennifer L. Spratlin, M. Brent McHenry, Asim Amin - Journal of Clinical Oncology 2017 cited by 508

  16. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

    Authors: Toni K. Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suárez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Marine Gross‐Goupil, Alexandr Poprach, Maria De Santis, Fabio A. Schutz, Se Hoon Park, Dmitry Nosov, Camillo Porta, Jae‐Lyun Lee, Xavier García del Muro, Elisa Biscaldi, Ray Manneh Kopp, Mototsugu Oya, He Li, Aobo Wang, Rodolfo F. Perini, Donna Vickery, Laurence Albigès, Brian I. Rini - New England Journal of Medicine 2024 cited by 142

  17. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Authors: Andrew J. Armstrong, Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. García, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa Pickering, Christopher W. Ryan, Andrew Protheroe, Christine M. Lusk, Sadie Oberg, Daniel J. George - The Lancet Oncology 2016 cited by 424

  18. LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

    Authors: Laurence Albigès, Brian I. Rini, Katriina Peltola, G.A. De Velasco Oria, Mauricio Burotto, C. Suarez Rodriguez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, M. Gumus, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, B. Venugopal, Andrew Z. Wang, R. Perini, Donna Vickery, T.B. Powles, Toni K. Choueiri - Annals of Oncology 2023 cited by 53

  19. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

    Authors: Robert J. Motzer, Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R. Plimack, Philippe Barthélémy, Hans J. Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K. Choueiri, Brian I. Rini, Pamela Salman, Christian Kollmannsberger, Scott S. Tykodi, Marc‐Oliver Grimm, Howard Gurney, Raya Leibowitz‐Amit, Poul Geertsen, Asim Amin, Yoshihiko Tomita, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Journal for ImmunoTherapy of Cancer 2020 cited by 225

  20. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium

    Authors: Ziad Bakouny, Talal El Zarif, Shaan Dudani, J. Connor Wells, Chun Loo Gan, Frede Donskov, Julia Shapiro, Ian D. Davis, Francis Parnis, Praful Ravi, John A. Steinharter, Neeraj Agarwal, Ajjai Alva, Lori Wood, Anil Kapoor, José Manuel Ruiz Morales, Christian Kollmannsberger, Benoit Beuselinck, Wanling Xie, Daniel Y.C. Heng, Toni K. Choueiri - European Urology 2022 cited by 106

  21. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy

    Authors: Siamak Daneshmand, Clint Cary, Timothy A. Masterson, Lawrence H. Einhorn, Nabil Adra, Stephen A. Boorjian, Christian Kollmannsberger, Anne Schuckman, Alan So, Peter C. Black, Aditya Bagrodia, Eila C. Skinner, Mehrdad Alemozaffar, Timothy C. Brand, Scott E. Eggener, Phillip M. Pierorazio, Kelly Stratton, Lucia Nappi, Craig R. Nichols, Chunqiao Luo, Ming Li, Brian Hu - Journal of Clinical Oncology 2023 cited by 103

  22. Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.

    Authors: Nizar M. Tannir, Bernard Escudier, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Michael B. Atkins, Christian Kollmannsberger, Marc‐Oliver Grimm, Yoshihiko Tomita, Brian I. Rini, Ruiyun Jiang, Heshani Desilva, Chung‐Wei Lee, Robert J. Motzer - Journal of Clinical Oncology 2024 cited by 46

  23. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

    Authors: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, David Leung, Shruti Shally Saggi, Chung‐Wei Lee, M. Brent McHenry, Robert J. Motzer - European Urology 2021 cited by 80

  24. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma

    Authors: Jack V. W. Bacon, Matti Annala, Maryam Soleimani, Jean‐Michel Lavoie, Alan So, Martin Gleave, Ladan Fazli, Gang Wang, Kim N., Christian Kollmannsberger, Alexander W. Wyatt, Lucia Nappi - Clinical Genitourinary Cancer 2020 cited by 55